Royalty Pharma to Acquire Royalty Interest in Amgen’s Imdelltra for up to $950 Million
NEW YORK, NY, August 25, 2025 – Royalty Pharma plc (Nasdaq: RPRX) today announced that it has acquired a royalty interest in Amgen’s Imdelltra, a first-in-class DLL3 targeting bispecific T-cell engager (BiTE), from BeOne Medicines for $885 million upfront.